Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria

Leukemia

Volumn 26, Issue 4, 2012, Pages 716-719

  Finazzi, G ^a   Carobbio, A ^a   Thiele, J ^b   Passamonti, F ^c   Rumi, E ^d   Ruggeri, M ^e   Rodeghiero, F ^e   Randi, M L ^f   Bertozzi, I ^f   Vannucchi, A M ^g   Antonioli, E ^g   Gisslinger, H ^h   Buxhofer Ausch, V ^h   Gangat, N ⁱ   Rambaldi, A ^a   Tefferi, A ⁱ   Barbui, T ^a  

^a OSPEDALI RIUNITI   (Italy)

^b UNIVERSITY OF COLOGNE   (Germany)

^c OSPEDALE DI CIRCOLO   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

^e SAN BORTOLO HOSPITAL   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

^g UNIVERSITY OF FLORENCE   (Italy)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ MAYO CLINIC   (United States)

Author keywords

aspirin; bleeding; essential thrombocythemia; myeloproliferative neoplasms; prefibrotic myelofibrosis

Indexed keywords

ACETYLSALICYLIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; CHILD; CONTROLLED STUDY; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; LEUKOCYTOSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MYELOFIBROSIS; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; THROMBOCYTHEMIA; THROMBOCYTOSIS;

EID: 84859650006     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.258     Document Type: Article

References (15)

1. Epstein E, Goedel A. Hämorrhagische thrombocythämie bei vasculärer schrumpfmilz. Virchows Arch f path Anat Physiol f klin Med 1934; 292: 233-248.
2. V617F mutation in essential thrombocythemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005; 131: 208-213.
3. Alvarez-Larran A, Cervantes F, Pereira A, Arellano-Rodrigo E, Pérez-Andreu V, Hernandez-Boluda J-C et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 2010; 116: 1205-1210.
4. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005; 128: 275-290. (Pubitemid 40216149)
5. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival and leukemic transition by treatment. Semin Hematol 1997; 34: 29-39. (Pubitemid 27063140)
6. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
7. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Harrison CA et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092-1097. (Pubitemid 47281402)
8. Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 2011; 29: 3179-3184.
9. Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study on 891 patients. Blood 2011; 117: 5857-5859.
10. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353: 33-45. (Pubitemid 41007805)
11. Campbell PJ, Bareford D, Erber WN, Wilkins BS, Wright P, Buck G et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol 2009; 27: 2991-2999.
12. Thiele J, Kvasnicka HM, Vardiman JW, Orazi A, Franco V, Gisslinger H et al. Bone marrow fibrosis and diagnosis of essential thrombocythemia. J Clin Oncol 2009; 27: e220-e221.
13. Moxon-Emre I, Schlichter LC. Neutrophil depletion reduces blood-brain breakdown, axon injury, and inflammmation after intracerebral hemorrhage. J Neuropathol Exp Neurol 2011; 70: 218-235.
14. Fang H, Sun C, Xu L, Owen RJ, Auth RD, Snoy PJ et al. Neutrophil elastase mediates pathogenic effects of antrax lethal toxin in the murine intestinal tract. J Immunol 2010; 185: 5463-5467.
15. Harrison C, Barbui T. Aspirin in low-risk essential thrombocythemia, not so simple after all? Leuk Res 2011; 35: 286-289.